A year af­ter net­ting Take­da part­ner­ship, small mol­e­cule start­up arms it­self with some new cash

As small mol­e­cule com­pa­nies con­tin­ue to get se­ri­ous cash from in­vestors as well as back­ing from ma­jor phar­ma com­pa­nies such as Eli Lil­ly, Cal­i­for­nia-based Brid­Gene Bio­sciences is look­ing to stay ahead of the pack.

The com­pa­ny an­nounced Wednes­day morn­ing it pulled in a $38.5 mil­lion Se­ries B, which will be go­ing to­wards fur­ther de­vel­op­ing its plat­form, dubbed IM­TAC. The plat­form al­lows Brid­Gene to screen small mol­e­cules against a tar­get in live cells to dis­cov­er pos­si­ble drug can­di­dates, main­ly in un­drug­gable tar­gets, in­clud­ing for can­cers. The com­pa­ny will al­so be look­ing to ex­pand its small mol­e­cule li­brary as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER